$92.7m
$92.7m of $132m target
Georgiamune, Inc.
Georgiamune is a clinical stage biotechnology company developing therapies that reprogram immune responses. Its research targets immune pathways involved in autoimmune disease and cancer to produce new treatment candidates.
- Appearances
- 1
- Categories
- 1
- First seen
- 13 September 2026
- Latest
- 13 September 2026
01/
Appearance history
1 appearanceThis page records every appearance of the same entity in the reviewed RiseFinder exports. Rankings keep the original category, period and measurement direction.
02/
Get email updates
Join the listGet early signals on the websites, apps, repositories and startups gaining momentum. Join the list for Risefinder email briefings.
Be first to receive the briefing.